ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity
- 385 Downloads
Capecitabine, an orally available prodrug of 5-FU, requires activation by carboxylesterase (CES) enzymes present in the liver to generate 5′-deoxy-5-flurocytidine ribose (5′-DFCR). The deamination of the latter by cytidine deaminase gives 5′-deoxy-5-fluorouridine ribose (5′-DFUR). Finally, the conversion of 5′-DFUR to the cytotoxic drug 5-FU, occurs primarily in the tumour and is catalyzed by thymidine phosphorylase (TP). Accordingly, it was surmised that events associated with an increase of TP levels should enhance the potency of capecitabine and its metabolites. EGFR inhibition was found to be one such event. The observed synergy between gefitinib and 5′-DFUR has inspired the design of single molecules capable of acting as prodrugs of both an EGFR inhibitor and 5-FU. Here, we report on the synthesis and characterization of one such molecule, ZRX1, that consists of an acetylated 5′-DFCR moiety linked to a quinazoline inhibitor of EGFR through an alkyl dicarbamate spacer that requires CES activation to generate the two active metabolites. Our results showed that ZRX1 was ineffective as an intact molecule. However, when CES was present, ZRX1 induced an increase in EGFR inhibition, TP expression, DNA damage and apoptosis. ZRX1 was, at least, 3-fold more potent than capecitabine and 5′-DFUR and recapitulated the effects of the combination treatments. LC-MS analysis showed that in the presence of CES, ZRX1 is metabolized into a mixture of bioactive quinazoline derivatives and 5′-DFCR derived metabolites. Our results in toto, suggest that capecitabine-based EGFR targeting combi-molecules of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5′-DFUR or single EGFR inhibitors and equivalent potency when compared with combinations of EGFR inhibitors + 5′-DFUR.
KeywordsCancer therapy EGFR inhibition Capecitabine Combi-molecule Thymidine phosphorylase
We would like to thank the Canadian Institute of Health Research for their financial support of the project (201816 CIHR Operating Grant MOP-49440). In addition, we would like to express our gratitude to the Research Institute /McGill University Health Center, the McGill/Canadian Institute Health Research Drug development training Program and Fonds de recherche du Québec – Santé (FRQS) for providing Maria Ait-Tihyaty with generous scholarships.
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281CrossRefPubMedGoogle Scholar
- 6.Mimori K, Ueo H, Kuroki T, Shiraishi T, Creer S, Taylor S, Ishii H, Mori M (2004) Prediction of 5′-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes. Oncol Rep 12(1):19–23PubMedGoogle Scholar
- 10.Talbot DC, Moiseyenko V, Van Belle S, O’Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86:1367–1372PubMedCentralCrossRefPubMedGoogle Scholar
- 12.Magne N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renee N, Marchetti S, Etienne MC, Milano G (2003) ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 9:4735–4742PubMedGoogle Scholar
- 13.Ait-Tihyaty M, Rachid Z, Mihalcioiu C, Jean-Claude BJ (2012) Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda((R)). Breast Cancer Res Treat 133(1):217–226Google Scholar
- 14.Nair P (2005) Epidermal growth factor receptor family and its role in cancer progression. Curr Sci 88:890–898Google Scholar
- 19.Rachid Z, Macphee M, Williams C, Todorova M, Jean-Claude BJ (2009) Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorg Med Chem Lett 19(18):5505–5509CrossRefPubMedGoogle Scholar
- 20.Larroque-Lombard AL, Todorova M, Qiyu Q, Jean-Claude B (2011) Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK. Chem Biol Drug Des 77(5):309–318Google Scholar
- 22.MacPhee M, Rachid Z, Todorova M, Qiu Q, Belinsky G, Jean-Claude BJ (2011) Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Invest New Drugs 29(5):833–845Google Scholar
- 24.Todorova MI, Larroque AL, Dauphin-Pierre S, Fang YQ, Jean-Claude BJ (2010) Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther 9(4):869–882Google Scholar
- 32.Trempe GL 1976 Human breast cancer in culture. Recent Results Cancer Res Fortschritte der Krebsforschung (57):33–41Google Scholar
- 35.Hosokawa M, Satoh T (2002) Measurement of carboxylesterase (CES) activities. Current protocols in toxicology / editorial board, Mahin D Maines (editor-in-chief) et al., Chapter 4:Unit4 7Google Scholar
- 36.De Angelis P, Svendsrud DH, Kravik KL, Stokke T (2006) Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 5(20)Google Scholar
- 39.Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16(9):2977–2985PubMedGoogle Scholar
- 40.Shindoh H, Nakano K, Yoshida T, Ishigai M (2011) Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans—toxicological implications. J Toxicol Sci 36(4):411–422Google Scholar